Olaparib azd2281

CNE1, CNE2 and HNE1 were obtained from the Molecular Medicine and Cancer Research Center, Chongqing Medical University. The cells were grown in RMPI-1640 medium (HyClone, Logan City, Utah, USA) with 10% fetal bovine serum (HyClone, Logan City, Utah, USA) at 37 °C with 5% CO₂. The lentivirus-mediated shNFBD1 and shControl were purchased from Genechem, Shanghai,
China. PARP inhibitor Olaparib (AZD2281) was obtained from MedChemExpress (Princeton, NJ, USA). Hoechst 33342 were purchased from Beyotime Institute of Biotechnology (Nantong, China).The antibodies used in this study were anti-NFBD1 (Abcam, UK); anti-RAD51, anti-BRCA1, anti-BRCA2, and anti-PARP1 (Santa Cruz Biotechnology, USA); anti-γ-H2AX (Cell Signaling Technology, Danvers, MA, USA).

The RWPE-1, LNCaP, 22RV1, PC3, and DU145 cell lines were obtained from Zhong Qiao Xin Zhou Biotechnology Co., Ltd. (Shanghai, China). HEK-293T cells were purchased from Kunming Cell Bank (Kunming, China). The cells were cultured and aliquots were stored in liquid nitrogen for future use. RWPE-1 cells were cultured in customized medium (ZQXZ Bio, Shanghai, China). LNCaP, 22RV1, and DU145 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin (P/S) at 37 °C in a 5% CO₂ environment. PC3 cells were cultured in ATCC-formulated F-12K medium supplemented with 10% FBS and 1% P/S at 37 °C in a 5% CO₂ environment. HEK-293T cells were cultured in DMEM/HIGH GLUCOSE (HyClone, Logan, Utah, USA) supplemented with 10% FBS and 1% P/S at 37 °C in a 5% CO₂ environment. Olaparib (AZD2281) and ML216 (CID-49852229) were purchased from MedChemExpress (Monmouth Junction, NJ, USA).